Review of olmesartan medoxomil in achieving guideline-recommended target BP goals and implications for managed care

Current Hypertension Reviews

Volumn 8, Issue 3, 2012, Pages 190-195

  Saseen, Joseph J ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Blood pressure; Clinical guidelines; Goal BP; Hypertension; Managed care; Olmesartan medoxomil

Indexed keywords

AZILSARTAN MEDOXOMIL; CANDESARTAN HEXETIL; DIPEPTIDYL CARBOXYPEPTIDASE; EPROSARTAN; IRBESARTAN; LOSARTAN POTASSIUM; OLMESARTAN; RAMIPRIL; RENIN; TELMISARTAN; VALSARTAN;

ARTICLE; BLOOD PRESSURE; CHRONIC KIDNEY DISEASE; DECISION MAKING; DIABETES MELLITUS; EVIDENCE BASED PRACTICE; HEALTH CARE COST; HUMAN; HYPERTENSION; MANAGED CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME;

EID: 84870220776     PISSN: 15734021     EISSN: 18756506     Source Type: Journal    
DOI: 10.2174/157340212803530439     Document Type: Article

References (31)

1. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560-72.
2. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Agespecific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903-13.
3. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics-2012 update: a report from the American Heart Association. Circulation 2012; 125: e2-e220.
4. Mancia G, De Backer G, Dominiczak A, et al. 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens 2007; 25: 1751-62.
5. Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009; 27: 2121-58.
6. Cushman WC, Evans GW, Byington RP, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010; 362: 1575-85.
7. American Diabetes Association. Standards of medical care in diabetes-2012. Diabetes Care 2012; 35(Suppl 1): S11-63.
8. Saseen JJ, Maclaughlin EJ. Hypertension. In: Dipiro JT, Ed. Pharmacotherapy: a pathophysiological approach. 7th ed. New York: McGraw Hill 2007; pp 139-71.
9. Israili ZH. Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension. J Hum Hypertens 2000; 14(Suppl 1): S73-86.
10. Edarbi (azilsartan medoxomil) tablets: US prescribing information. Deerfield, IL: Takeda Pharmaceuticals America, Inc.; 2011.
11. Warner GT, Jarvis B. Olmesartan medoxomil. Drugs 2002; 62: 1345-53; discussion 54-6.
12. Atacand (candesartan cilexetil) tablet: US prescribing information. Wilmington, DE: AstraZeneca LP; 2012.
13. Teveten (eprosartan mesylate) tablet: US prescribing information. North Chicago, IL: Abbott Laboratories; 2012.
14. Avapro (irbesartan) tablet: US prescribing information. New York, NY: Bristol-Myers Squibb Sanofi-Synthelabo Partnership; 2012.
15. Cozaar (losartan potassium) tablet, film coated: US prescribing information. Whitehouse Station, NJ: Merck Sharp & Dohme Corporation; 2011.
16. Benicar (olmesartan medoxomil) tablet, film coated: US prescribing information. Parsippany, NJ: Daiichi Sankyo, Inc.; 2011.
17. Micardis (telmisartan) tablet: US prescribing information. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc; 2012.
18. Diovan (valsartan) capsule: US prescribing information. East Hanover, NJ: Novartis Pharmaceuticals Corp; 2012.
19. Rosendorff C, Black HR, Cannon CP, et al. Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation 2007; 115: 2761-88.
20. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1003.
21. Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547-59.
22. Oparil S, Chrysant SG, Kereiakes D, et al. Results of an olmesartan medoxomil-based treatment regimen in hypertensive patients. J Clin Hypertens (Greenwich) 2008; 10: 911-21.
23. Kereiakes DJ, Neutel JM, Punzi HA, Xu J, Lipka LJ, Dubiel R. Efficacy and safety of olmesartan medoxomil and hydrochlorothiazide compared with benazepril and amlodipine besylate. Am J Cardiovasc Drugs 2007; 7: 361-72.
24. Kereiakes DJ, Neutel J, Stoakes KA, et al. The effects of an olmesartan medoxomil-based treatment algorithm on 24-hour blood pressure levels in elderly patients aged 65 and older. J Clin Hypertens (Greenwich) 2009; 11: 411-21.
25. Neutel JM, Kereiakes DJ. An olmesartan medoxomil-based treatment algorithm is effective in achieving 24-hour BP control in patients with type 2 diabetes mellitus, regardless of age, race, sex, or severity of hypertension: subgroup analysis of the BENIFICIARY study. Am J Cardiovasc Drugs 2010; 10: 289-303.
26. Giles TD, Oparil S, Silfani TN, Wang A, Walker JF. Comparison of increasing doses of olmesartan medoxomil, losartan potassium, and valsartan in patients with essential hypertension. J Clin Hypertens (Greenwich) 2007; 9: 187-95.
27. Simons WR. Comparative cost effectiveness of angiotensin II receptor blockers in a US managed care setting: olmesartan medoxomil compared with losartan, valsartan, and irbesartan. Pharmacoeconomics 2003; 21: 61-74.
28. Miller LA, Wade R, Dai D, Cziraky MJ, Ramaswamy K, Panjabi S. Economic evaluation of four angiotensin II receptor blockers in the treatment of hypertension. Curr Med Res Opin 2010; 26: 1307-20.
29. Simons RW, Ram V, Ramaswamy K, Biskupiak J, Reiner E. Comparative effectiveness of angiotensin II receptor blockers [abstract PO-60]. J Clin Hypertens (Greenwich) 2010; 12(Suppl 1): A43.
30. Chapman RH, Yeaw J, Roberts CS. Association between adherence to calcium-channel blocker and statin medications and likelihood of cardiovascular events among US managed care enrollees. BMC Cardiovasc Disord 2010; 10: 29.
31. Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixeddose combinations improve medication compliance: a metaanalysis. Am J Med 2007; 120: 713-9.